However, since these biomarkers are not sensitive enough to predict kidney disease progression, various new biomarkers have been proposed recently such as neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1) and liver-type fatty acid-binding protein (L-FABP), and are under thorough clinical validations [2], [3]. This evidence concerns the gene HAVCR1 and kidney disorder.